评估tezepelumab用于慢性阻塞性肺疾病：是错失的靶点还是未满足的潜力？ - Suppr | 超能文献

Evaluating tezepelumab for COPD: a missed target or unmet potential?

作者信息

Cazzola Mario, Rogliani Paola, Matera Maria Gabriella

机构信息

Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', 00131 Rome, Italy.

Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', 00131 Rome, Italy.

出版信息

Lancet Respir Med. 2025 Jan;13(1):5-6. doi: 10.1016/S2213-2600(24)00381-3. Epub 2024 Dec 6.

DOI:10.1016/S2213-2600(24)00381-3

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Evaluating tezepelumab for COPD: a missed target or unmet potential?评估tezepelumab用于慢性阻塞性肺疾病：是错失的靶点还是未满足的潜力？

Lancet Respir Med. 2025 Jan;13(1):5-6. doi: 10.1016/S2213-2600(24)00381-3. Epub 2024 Dec 6.

2

Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.特泽佩umab对比安慰剂治疗中重度至非常重度慢性阻塞性肺疾病成人患者的疗效和安全性（COURSE）：一项随机、安慰剂对照的2a期试验

Lancet Respir Med. 2025 Jan;13(1):47-58. doi: 10.1016/S2213-2600(24)00324-2. Epub 2024 Dec 6.

3

Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?重度、未控制哮喘的未满足需求：特泽泊鲁单抗的抗 TSLP 疗法能否提供有价值的新治疗选择？

Respir Res. 2020 Oct 15;21(1):268. doi: 10.1186/s12931-020-01505-x.

4

NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma.NAVIGATOR：一项 3 期多中心、随机、双盲、安慰剂对照、平行分组试验，旨在评估特泽泊鲁单抗在成人和青少年中重度、未控制的哮喘中的疗效和安全性。

Respir Res. 2020 Oct 13;21(1):266. doi: 10.1186/s12931-020-01526-6.

5

CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma.CASCDE 研究：一项 2 期、随机、双盲、安慰剂对照、平行分组试验，旨在评估特泽鲁单抗对未控制哮喘患者气道炎症的影响。

Respir Res. 2020 Oct 13;21(1):265. doi: 10.1186/s12931-020-01513-x.

6

Tezepelumab: First Approval.特泽布尔单抗：首次批准。

Drugs. 2022 Mar;82(4):461-468. doi: 10.1007/s40265-022-01679-2.

7

SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma.来源：一项 3 期、多中心、随机、双盲、安慰剂对照、平行组试验，旨在评估特泽泊单抗在减少口服糖皮质激素依赖型哮喘成人中口服糖皮质激素使用的疗效和安全性。

Respir Res. 2020 Oct 13;21(1):264. doi: 10.1186/s12931-020-01503-z.

8

Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma.特泽布尔单抗：一种用于治疗严重未控制哮喘的新型生物疗法。

Expert Opin Investig Drugs. 2019 Nov;28(11):931-940. doi: 10.1080/13543784.2019.1672657. Epub 2019 Oct 10.

9

The Impact of Tezepelumab in Uncontrolled Severe Asthma: A Systematic Review of Randomized Controlled Trials.特泽佩umab对难治性重度哮喘的影响：随机对照试验的系统评价

Cureus. 2022 Dec 3;14(12):e32156. doi: 10.7759/cureus.32156. eCollection 2022 Dec.

10

Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers.通过小瓶和注射器、配套预填充注射器或自动注射器给药后tezepelumab的药代动力学、安全性和耐受性：一项在健康志愿者中的随机试验。

Clin Ther. 2021 Jan;43(1):142-155.e5. doi: 10.1016/j.clinthera.2020.11.014. Epub 2020 Dec 27.

引用本文的文献

1

Exacerbation control in chronic obstructive pulmonary disease with tezepelumab: insights from the COURSE trial.使用tezepelumab控制慢性阻塞性肺疾病急性加重：来自COURSE试验的见解。

J Thorac Dis. 2025 Jul 31;17(7):4379-4382. doi: 10.21037/jtd-2025-769. Epub 2025 Jul 29.